February 4, 2021, Shanghai, China— MicroPort^® CardioFlow Medtech Corporation (“MicroPort^® CardioFlow”, stock code: 2160), is successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK).

On April 15, 2020, MicroPort^® Scientific Corporation (Stock code: 00853) ("MicroPort^®"), announced that MicroPort^® CardioFlow ("MicroPort^® CardioFlow"), which is a subsidiary of MicroPort^®, had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction of seven prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million. After this round of fundraising, the investors will have an aggregate shareholding of 10.83% in MicroPort^® CardioFlow. J.P. Morgan Securities (Asia Pacific) Limited and Citigroup Global Markets Asia Limited acted as co-placement agents in the transaction.

On September 19, 2019, the first post-marketing implantation of the VitaFlow^® Valve System and Alwide^® Balloon in Lingnan Region was successfully performed by the team of Prof. Luo Jianfang at Guangdong General Hospital.